Efficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2

Sugimoto, Kumiko; Kim, Soo Ki; Kim, Soo Ryang; Kobayashi, Motoyasu; Kato, Airi; Morimoto, Eri; Imoto, Susumu; Kim, Chi Wan; Tanaka, Yasuhito; Kudo, Masatoshi; Yano, Yoshihiko; Hayashi, Yoshitake

doi:10.1159/000448823

Cited by 4 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inosine triphosphatase (ITPA) polymorphism may influence hemoglobin levels and incidence of ribavirin dose reduction during sofosbuvir plus ribavirin therapy [26]. Although we did not measure the ITPA polymorphism in the present study as previously studies have [28], it was reported that the ITPA polymorphism did not appear to correlate with clinical outcome [24,29,30], and we do not have to measure the ITPA polymorphism before the 12-week treatment of sofosbuvir plus ribavirin. Moreover, the adherence of these drugs for 12 weeks appeared much better than the previous standard of care against HCV GT-2 with peginterferon plus ribavirin for 24 weeks [8,9].…”

Section: Discussionmentioning

confidence: 91%

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin

Nakamura

Yasui

Haga

et al. 2017

Biology

View full text Add to dashboard Cite

The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2. This retrospective study analyzed 114 Japanese HCV GT-2 patients treated for 12 weeks with 400 mg of sofosbuvir plus weight-based ribavirin daily. This treatment led to higher sustained virologic response at 12-weeks post-treatment (SVR12) rates in both treatment-naïve and treatment-experienced patients. The efficacy of this treatment in compensated cirrhotics was the same as that in patients with chronic hepatitis. HCV GT-2a infection and lower estimated glomerular filtration rates (eGFR) tended to be associated with SVR12. Of 114 patients, 113 completed the combination of sofosbuvir plus ribavirin for 12 weeks. Seven patients without SVR12 did not have HCV NS5B-S282 mutations. The overall SVR12 rate was 90.4% (103 of 114). More effective therapeutic options with less adverse events are desired to achieve higher SVR rates in HCV GT-2 Japanese patients.

show abstract

Section: Discussionmentioning

confidence: 91%

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin

Nakamura

Yasui

Haga

et al. 2017

Biology

View full text Add to dashboard Cite

show abstract

“…In addition, since IFN also causes anaemia, it is possible that RBV dose reduction during the IFN era was more profound and/or occurred earlier in the treatment course. 45 Finally, as the DAA treatment regimen only lasted for 12 weeks (vs 24–48 weeks in the IFN era), patients may have tolerated their haemoglobin decline better, resulting in less RBV reduction even in the dose reduction population. Compared with individual studies in which RBV dose reduction data were often available in only few participants, our study included 299 patients with RBV dose reduction from six real-world studies, thus allowing for more precise estimate of SVR12 and potential effects of RBV dose reduction on SVR12.…”

Section: Discussionmentioning

confidence: 99%

Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis

Wei

Yeo

et al. 2018

BMJ Open Gastroenterol

View full text Add to dashboard Cite

BackgroundSofosbuvir plus ribavirin (SOF+RBV) for 12 weeks is the standard treatment for chronic hepatitis C (CHC) genotype 2 (GT2) in most of Asia despite availability of new CHC medications. SOF-RBV real-world effectiveness has only been reported in small and/or single-centre studies. Our goal was to determine the real-world effectiveness of 12-week SOF+RBV therapy for CHC GT2 in Asia.MethodsA systematic search on PubMed and Embase was conducted through 30 June 2017. We identified full articles and conference proceedings of at least 10 adult patients with CHC GT2 treated with SOF+RBV for 12 weeks under real-world setting in Asia.ResultsA total of 2208 patients from 13 studies were included. The pooled sustained virological response 12 weeks after the end of treatment (SVR12) was 95.8% (95% CI 94.6% to 96.9%) with non-significant heterogeneity (I2=34.4%). Anaemia (27.9%) was the most common adverse event (AE), with serious AEs in 2.0% and only 0.7% discontinued therapy prematurely. In subgroup analyses, patients with cirrhosis had 8.7% lower SVR12 than non-cirrhotic patients (P<0.0001), and treatment-experienced patients had 7.2% lower SVR12 than treatment-naïve patients (P=0.0002). Cirrhotic treatment-experienced patients had the lowest SVR12 at 84.5%. There were no significant differences in pooled SVR12 among patient subgroups: RBV dose reduction versus no dose reduction (P=0.30); hepatocellular carcinoma (HCC) versus no HCC (P=0.10); GT 2a versus 2b (P=0.86); and <65 vs ≥65 years of age (P=0.20).ConclusionsSOF+RBV for 12 weeks was safe and effective for patients with CHC GT2 in Asia, although those with cirrhosis and prior treatment failure had a lower pooled SVR12 rate.Trial registration numberCRD42017067928.

show abstract

“…DAA therapy with Sofosbuvir (Gilead Sciences), the oral nucleotide analog inhibitor of HCV-specific nonstructural protein (NS)5B polymerase, plus ribavirin (RBV) for patients infected with HCV genotype 2 has demonstrated a higher rate of sustained virological response at 12 weeks after treatment (SVR12) and greater safety than treatment with pegylated interferon (peg-IFN) and RBV [17][18][19][20][21][22] .…”

mentioning

confidence: 99%

Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2

Seo

Kim²,

Kim³

et al. 2017

Dig Dis

Self Cite

View full text Add to dashboard Cite

Background: Sofosbuvir plus ribavirin (RBV) therapy showed higher sustained virological response at 12 weeks after treatment (SVR12) than pegylated interferon (peg-IFN) plus RBV; however, liver function, fibrosis, and hepatocellular carcinoma markers have not been assessed so far. Summary: Patients (n = 21) receiving Sofosbuvir plus RBV and those (n = 24) receiving peg-IFN plus RBV were enrolled in this study. Changes in alanine aminotransferase (ALT) and α-fetoprotein (AFP) levels, platelet (PLT) counts, FIB-4, and aspartate aminotransferase-to-platelet ratio index (APRI) in both groups were assessed in patients achieving SVR12. Also, fibrosis regression was assessed using pathophysiological biomarkers, such as hyaluronic acid, bone morphogenetic protein 7 (BMP-7), and connective tissue growth factor (CTGF) in the Sofosbuvir plus RBV group. In both groups, while the reduction in ALT levels was significant that of AFP was not. Compared with the baseline, although serum PLT count at the end of treatment (EOT) was significantly higher in the Sofosbuvir plus RBV group, it was significantly lower in the peg-IFN plus RBV group. Although a significant decline in fibrosis markers such as FIB-4 and APRI was observed between the baseline and at EOT in the Sofosbuvir plus RBV group, no significant change of these markers was observed in the peg-IFN plus RBV group. Moreover, BMP-7 and CTGF were significantly lower at EOT than the baseline in the Sofosbuvir plus RBV group. Key Message: The treatment with Sofosbuvir plus RBV results in not only a higher SVR, but also improves the liver function and the degree of fibrosis.

show abstract

Efficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2

Cited by 4 publications

References 22 publications

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin

Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis

Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2

Contact Info

Product

Resources

About